RxLink’s Post

🌐 #GlobalBiosimilarsWeek shines a spotlight on biosimilars' potential to revolutionize health care access. Part 2 of this insightful series delves into the complex web of payer and pharmacy benefit managers (PBM) policies that impact biosimilar access, from formulary placements to cost-sharing dynamics. Biosimilars offer vital cost savings, yet PBM and payer policies often create barriers, favoring originators due to rebate structures. Addressing these policy issues—whether through transparency or reform—could open doors to more affordable health care for patients nationwide. Let's work towards a biosimilar-friendly future that prioritizes accessibility and affordability! https://lnkd.in/eMF7Hi2q

Thank you, Fabrizio Gambino, for leading us in helping people on their journey to better health. With GLP-1 agonists, proper support from trained clinicians is vital for safe and effective weight loss. As Chief Clinical Officer of RPM Healthcare, I am proud to lead a team of passionate nurses dedicated to this mission. People on weight loss medications can lose muscle, and regain fat, making it crucial to promote sustainable weight loss methods. Our clinicians provide expertise and empathy, making a meaningful impact on patients' health journeys. We don't work with disease- we work with people!!!! If you are interested in learning about RPM - ask me a question. #RPM, #remotepatientmonitoring #weightloss

No one should have to skip the care – or the medications – they need because of the #costofhealthcare and yet, numerous studies show that even those with employer-sponsored benefits often do. That is why I am so proud of #RxBenefits' transparent, client-aligned #pharmacybenefitoptimization model that enables self-funded plans provide valuable, affordable #pharmacybenefits. Curious to see if we can help you? Learn more here: https://lnkd.in/etjmdVT9

A recent study by BCBS highlights that over half of patients prescribed Wegovy and Saxenda discontinue treatment early, limiting effectiveness. This underscores the importance of patient adherence for achieving weight loss goals. At RPM Healthcare, we are dedicated to improving outcomes through our Weight Management Program, which supports pre-authorizations and patient adherence. For those who don't qualify for medications, our lifestyle modules, care coaches, and interactive communications offer significant support. Recently, a member achieved a 30lb weight loss with excellent lab results, and is no longer pre-diabetic. Personalized insights empower our members and showcase RPM's transformative impact on healthcare. #weightloss #weightmanagement

"Discover #FDA insights on how payers drive clinical trial success and enhance patient outcomes in 2024." #PayersInClinicalTrials #FDAInsights #healthcare #DistilINFO.https://https://lnkd.in/dVQJJSes

This is a timely post: The PBM model is a 'dead man walking.' What comes next? Take a look and let me know what you think. It is timely because I wrote my blog post for the week of 10/21 on my experience with my PBM. My solution is to involve people (patients and caregivers) in the process. PEOPLE are the ones totally forgotten in this money-driven healthcare system. Here is the link to review.  https://lnkd.in/ek8bCstz. Let me know your thoughts

Unlock the secrets to better patient adherence! Check out the insightful partner content article on "Patient Adherence to Specialty Meds." Discover innovative strategies and trends shaping the healthcare landscape. Dive in now: https://brnw.ch/21wHPG4 DrFirst, Inc. #PatientAdherence #HealthcareInsights #SponsoredContent

What opportunities exist for healthcare organizations looking to support patients who rely on specialty medications?   In this article, CarelonRx president Paul Marchetti explains our commitment to patient-centered care and how it drives affordability, accessibility, and collaboration within the healthcare system. https://lnkd.in/enXeE3k6 #HealthcareLeadership #PatientCare #SpecialtyMedications

💡 What CMS’s proposed reimbursement codes could mean for the digital therapeutics industry The Centers for Medicare & Medicaid Services Services (#CMS) has proposed new #CPT payment codes for #DigitalTherapeutics, marking a significant step towards widespread reimbursement for the #DTx products. Previously, CMS introduced Level II #HCPCs codes for behavioral health digital therapeutics, which mainly applied to Medicare and Medicaid. The new CPT codes, applicable to all payers, could significantly expand coverage. The proposed codes (GMBT1, GMBT2, and GMBT3) allow physicians to bill for digital therapeutics similarly to how they bill for vaccines, covering initial provision, patient education, and ongoing management services. Susanne Gruber, #DTx Channel #Ambassador, comments 👇 Payer coverage is needed for a scaleable and sustainable reimbursement business model. This introduction of new CPT payment codes for DTx applicable to all payers is another step to make this GoToMarket pathway more attractive. Compensation of HCPs for explaining the DTx and monitoring the patients' data will surely drive the HCP adoption. But, why only for mental health conditions? I hope this is a clear support of DTx and that it won't take too long to expand it to other TAs. ✔ There is more news, comments, analyses & #competitor and #market trends on Allis.Health, the global analyst platform for the #digitalhealth & healthcare industry. 🌐https://allis.health/ Want to explore further? 💡 Contact us at hello@allis.health to arrange a demo session and get started with a free trial. #digitalhealth #DTx #digitaltherapeutics #marketinsights

340B can be a powerful tool for healthcare equity by creating a ripple effect where drug savings for safety-net providers translate into expanded services and healthier communities. As technology to manage drug discounts bridges the gap between 340B and even MDRP, a more streamlined system could be effective in unlocking the program's full potential, allowing cost savings to flow directly to patients and fuel further progress in affordable care. #340B #Healthcare #MDRP